 |
SYDNEY, June 17, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to Kazia's paxalisib for the treatment of atypical rhabdoid / teratoid tumors (AT/RT), a...
With many Aussies now working from home due to Government-mandated restrictions, there may be concerns that staying home could be driving up energy ...
Putting your house on the market can be a stressful experience, especially when you’re worried about how much it will cost. But there are several ...
Strong customer authentication (SCA), which is as an obligation since January 1, 2021, implies that any Cardholder Initiated Transaction (CIT) mus...
To start with, there is a general belief that technology is about innovation. Yes! That’s just right. However, what is not always clear to eve...
The journey of a thousand miles begins with a single step. Through the years, Oman has made giant strides as a nation. The Sultanate’s march towa...
Sydney is known to be a startup hub because of the attractive opportunities for business-minded people and the perks of living in the city. Innovati...